{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32.6","upperLimit":"71.8","value":"52.2"},{"groupId":"OG001","lowerLimit":"31.2","upperLimit":"74.0","value":"52.6"},{"groupId":"OG002","lowerLimit":"3.9","upperLimit":"34.1","value":"19"},{"groupId":"OG003","lowerLimit":"43.0","upperLimit":"83.0","value":"63"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"22"}],"units":"Participants"}],"description":"The Kaplan-Meier method will be used to estimate 5-year EFS, defined as the time from study enrollment to disease progression or recurrence, second malignant neoplasm, or death from any cause, or to date of last contact. Estimates are reported with 95% confidence intervals.","dispersionType":"95% Confidence Interval","groups":[{"description":"SPNET patients who received regimen A (no carboplatin / no isotretinoin)","id":"OG000","title":"Regimen A (SPNET Patients)"},{"description":"SPNET patients who received regimen B (carboplatin / no isotretinoin)","id":"OG001","title":"Regimen B (SPNET Patients)"},{"description":"SPNET patients who received regimen C (no carboplatin / isotretinoin)","id":"OG002","title":"Regimen C (SPNET Patients)"},{"description":"SPNET patients who received regimen D (carboplatin / isotretinoin)","id":"OG003","title":"Regimen D (SPNET Patients)"}],"paramType":"NUMBER","populationDescription":"Eligible SPNET patients are included.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Percent Probability of Event-free Survival (EFS) for Patients With Supratentorial Primitive Neuroectodermal Tumor (SPNET)","type":"PRIMARY","unitOfMeasure":"Percent Probability"}